Bio-Pharm Archives - 17 중 13 번째 페이지

Celltrion Establishes Subsidiary in Vietnam

Celltrion has officially entered the ASEAN market by establishing a local subsidiary in Vietnam. Following the company's tradition of having its top executives spearhead entry into key markets, Chairman Seo…

Cheon Okhyeon

2024-09-30

Celltrion Launches Zymfentra Media Campaign in the U.S.

Celltrion announced on the 27th that it has launched a media campaign in the U.S. for "Zymfentra," the world’s only infliximab subcutaneous (SC) formulation for treating autoimmune diseases. The campaign…

Cheon Okhyeon

2024-09-27

HK inno.N's K-CAB Receives Approval in Malaysia

HK inno.N's novel drug for gastroesophageal reflux disease (GERD), K-CAB, has received marketing approval in Malaysia. HK inno.N announced on the 26th that K-CAB tablets (ingredient: Tegoprazan) were recently approved…

Cheon Okhyeon

2024-09-26

Samsung Biologics Unveils Two New CDO Platforms

Samsung Biologics announced on the 25th that it has introduced two new Contract Development Organization (CDO) platforms at the ‘2024 Bio Process International (BPI)’ conference, a global bio conference. BPI…

Cheon Okhyeon

2024-09-25

12 Healthcare Stocks Including Celltrion Added to K-Value Up Index

The government has selected the ‘Korea Value Up’ Index as part of its efforts to address the Korea Discount, and 12 stocks from the healthcare sector have been included in…

Cheon Okhyeon

2024-09-24

"Lunit Eyes Treatment Solutions, Raising Hopes for Increased Corporate Value"

Lunit, a leading medical AI company focused on developing solutions that extend beyond diagnosis into treatment, is expected to see a steady increase in corporate value, according to industry analysts.…

Jang Jawon

2024-09-24

Yuhan Corporation to Receive $60 Million in Royalties LECLAZA

Yuhan Corporation announced on the 11th that it will receive $60 million (approximately 80 billion KRW) in commercialization royalties for its non-small cell lung cancer treatment "lazertinib" (marketed in Korea…

Cheon Okhyeon

2024-09-11

D&D Pharmatech's New Drug Candidate Approved for Phase 2 Clinical Trial in Multiple Sclerosis in the U.S.

The U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the Phase 2 clinical trial of "NLY01," a new drug candidate being developed by…

Jang Jawon

2024-09-03

Hanmi Pharmaceutical Board Rejects Nomination of Lim JongYoon as CEO

Park Jaehyun, CEO of Hanmi Pharmaceutical, retained his position following a board decision that rejected the proposal to appoint Lim Jongyoon, an internal director, as CEO. On August 2, Hanmi…

Cheon Okhyeon

2024-09-02

SK Biopharmaceuticals Aims to Become a Global RPT Leader by 2027

SK Biopharmaceuticals has set an ambitious goal to emerge as a global player in the radiopharmaceutical(RPT) sector within the next three years. The company plans to strengthen its capabilities through…

Cheon Okhyeon

2024-08-30